What's Happening?
Roche has decided to halt the development of two drugs for Huntington's disease, tominersen and RG6496, following unsatisfactory results in clinical trials. Tominersen, developed in collaboration with Ionis, failed to meet efficacy objectives in the phase
2 GENERATION HD2 study, despite achieving biomarker goals. This decision follows a previous setback in the phase 3 GENERATION HD1 trial. RG6496, another antisense candidate, was also discontinued after early trials indicated it would not be viable for long-term treatment. Roche communicated these decisions to patient organizations, emphasizing the importance of transparency and the need to focus on other research avenues.
Why It's Important?
The discontinuation of these drug candidates represents a significant setback in the search for effective treatments for Huntington's disease, a debilitating neurodegenerative disorder. This decision impacts patients and families hoping for new therapeutic options. It also highlights the challenges faced in developing treatments for complex genetic disorders. The failure of these trials underscores the need for continued research and innovation in the field, as well as the importance of managing expectations within the patient community. Despite this setback, Roche continues to explore other potential treatments, including a gene therapy candidate.
What's Next?
Roche will continue to focus on its remaining Huntington's disease candidate, a gene therapy acquired through its purchase of Spark Therapeutics. The company is likely to redirect resources and research efforts towards this and other promising avenues. The broader scientific community may also look to alternative approaches and collaborations to advance the understanding and treatment of Huntington's disease. Patient advocacy groups and researchers will likely continue to push for increased funding and support for innovative research in this area.
